How should anti-hypertensive medications be adjusted before screening for primary aldosteronism?
Journal
Journal of the Formosan Medical Association = Taiwan yi zhi
Journal Volume
123
Pages
S91-S97
Date Issued
2024
Author(s)
Chang, Yi-Yao
Lee, Ting-Wei
Wu, Ming-Hsien
Huang, Yen-Ta
Er, Leay Kiaw
Cheng, Hao-Min
Jia-Yin Hou, Charles
Chen, Szu-Tah
Liu, Feng-Hsuan
Abstract
Anti-hypertensive medications may affect plasma renin activity and/or plasma aldosterone concentration, misleading the interpretation of the aldosterone-to-renin ratio when screening for primary aldosteronism. The Task Force of Taiwan PA recommends that, when necessary, using α-adrenergic receptor blocking agents, centrally acting α-adrenergic agonists, and/or non-dihydropyridine calcium channel blockers should be considered to control blood pressure before screening for PA. We recommend temporarily holding β-adrenergic receptor blocking agents, mineralocorticoid receptor antagonists, dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and all diuretics before screening for PA. Further large-scale randomized controlled studies are required to confirm the recommendations.
Subjects
Aldosterone-to-renin ratio; Anti-hypertensive medications; Centrally acting α-adrenergic agonists; Nondihydropyridine calcium channel blockers; Primary aldosteronism; α-adrenergic receptor blocking agents
SDGs
Type
journal article